Navigation Links
Orexigen® Therapeutics Provides a Regulatory Update on Contrave® NDA
Date:6/3/2011

SAN DIEGO, June 3, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) announced today that it recently met with the Food and Drug Administration (FDA) regarding the New Drug Application for Contrave® (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight loss.  Orexigen sought the meeting to gain clarity on the approval deficiency stated in the Complete Response letter the Company received on January 31, 2011.  The Complete Response letter requested that the Company conduct a randomized, double-blind, placebo-controlled trial of sufficient size and duration to demonstrate that the risk of major adverse cardiovascular events in overweight and obese subjects treated with Contrave does not adversely affect the drug's benefit-risk profile.  

Orexigen submitted a specific proposal to address the theoretical cardiovascular risk cited in the approval deficiency and also explored approval for a narrowed indication in patients with lower cardiovascular risk until data from the proposed outcomes trial could be reviewed for label expansion.  The Division of Metabolic and Endocrinologic Products (DMEP) advised Orexigen that the proposed cardiovascular outcomes trial would not adequately address the approval deficiency and instead, requested a pre-approval cardiovascular outcomes trial that Orexigen believes is unprecedented and would generate significantly more information than is necessary or feasible.  Additionally, DMEP stated that it would not consider approving Contrave for a narrowed population without first reviewing data from a cardiovascular outcomes trial.  Finally, DMEP said that it intends to hold a general advisory committee early next year to discuss cardiovascular assessment for obesity therapeutics, and that any agreement reached on the desi
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
4. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
5. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
6. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
7. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
8. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
9. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
10. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
11. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... and LYON, France , Dec. 19, ... LLY ) and Adocia (Euronext Paris: FR0011184241 – ADOC) ... an ultra-rapid insulin, known as BioChaperone Lispro, for treatment ... BioChaperone Lispro relies on Adocia,s proprietary BioChaperone® technology and ... and Adocia will develop BioChaperone Lispro with the goal ...
(Date:12/17/2014)... SAN DIEGO , Dec. 17, 2014 ... and Volcano Corporation (NASDAQ: VOLC ), a global ... today announced that they have entered into a definitive merger ... offer to acquire all of the issued and outstanding shares ... equity purchase price of USD 1 billion (approx. EUR 800 ...
(Date:12/17/2014)... December 17, 2014 Revenue and earnings ... on research and development In the past 2013/14 ... by two percent to EUR 4.287 billion (last year: EUR ... 14 percent to EUR 360 million. "Overall, 2013/14 was a ... Michael Kaschke , President and CEO of Carl Zeiss AG. ...
Breaking Medicine Technology:Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8ZEISS Asserts its Position in Difficult Environment 2
... , WARSAW, Ind. , March 11 Zimmer ... in musculoskeletal care, will celebrate the 25th anniversary of the ...  The Natural Knee system offers a complete range of ...  Published clinical results show survivorship of the Natural Knee ...
... , March 11 Watson Pharmaceuticals, Inc. ... Food and Drug Administration (FDA) approval of TRELSTAR® 22.5 ... formulation of TRELSTAR®, a proven, simple and effective palliative ... launch, TRELSTAR® 22.5 mg is the first and only ...
Cached Medicine Technology:Zimmer Natural Knee Celebrates 25 Years of Excellence 2Zimmer Natural Knee Celebrates 25 Years of Excellence 3Zimmer Natural Knee Celebrates 25 Years of Excellence 4FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 2FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 3FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 4FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 5FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 6FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 7FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 8
(Date:12/19/2014)... It’s very easy to become overwhelmed with ... put to the wayside until Christmas and the New Year ... “itch” and that burning desire to just escape it all ... journey to Telluride with a no-fuss, affordable package. Montrose Days ... the resort, and ensure that all accommodations are met. Plus, ...
(Date:12/19/2014)... December 19, 2014 Energy Textiles ... are now available. Celliant, the world’s leading responsive ... and pillowcases. , There are a number of ... circulation, increased oxygenation and balanced body temperature; which ... and pain relief; enhanced athletic performance; and overall ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 SuperCloset raises ... SuperClone Rooms. SuperCloset continues to offer indoor growers the ... one of the new SuperClone Rooms with the award ... and turnkey indoor hydroponic grow room setup. , The ... world, SuperCloset’s SuperPonic SuperCloner 50 . ...
(Date:12/19/2014)... (PRWEB) December 20, 2014 An evening dress ... in a lady’s closet. Discount-Dress.com, a distinguished dresses retailer, has ... buy beautiful dresses in this great shopping platform. Customers ... to the staff's hard work, Discount-Dress.com has been accepted and ... a faster and easier shopping stage for clients. In order ...
(Date:12/19/2014)... FRIDAY, Dec. 19, 2014 (HealthDay News) -- New research warns parents ... young lives at risk. Nearly half of teen drivers killed ... that were at least 11 years old and often lacked important ... Eighty-two percent of teen drivers killed in crashes were in ... six to 10 years old, 31 percent were in cars 11 ...
Breaking Medicine News(10 mins):Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2Health News:Older Cars a Bad Choice for Younger Drivers 2
... By Steven Reinberg HealthDay Reporter , THURSDAY, ... medical groups gathered Thursday to warn of impending dangers ... speeding climate change. They believe the federal government, ... power to curtail such emissions, however. "The science ...
... New research shows that a less-toxic combination of a ... long-term remissions in some chronic lymphocytic leukemia patients. And ... therapy-related myelodysplastic syndrome and acute myeloid leukemia, which can ... these patients. The multi-institutional study, led by researchers ...
... sophisticated imaging test to probe for higher-level cognitive functioning in ... the view it presents is one that is blurred in ... the Feb. 25 online edition of the journal Brain ... in their function from minimally conscious state to the locked-in ...
... WEDNESDAY, Feb. 23 (HealthDay News) -- A new drug ... standard treatment of zoledronic acid (Zometa) for preventing fractures ... cancer, a new study suggests. In many patients, ... the first few years of diagnosis. As a result, ...
... (HealthDay News) -- A large number of dialysis patients ... radiation doses, and doctors should think about reducing these ... The researchers noted that many kidney disease patients ... that require them to undergo radiation procedures for diagnosis ...
... at Memorial Sloan-Kettering Cancer Center have found that change in ... is a poor predictor of prostate cancer and may lead ... 5,000 men was published online February 24 in the ... Associate Attending Research Methodologist in the Department of Epidemiology and ...
Cached Medicine News:Health News:Medical Groups Warn Of Climate Change's Potential Impact on Health 2Health News:Medical Groups Warn Of Climate Change's Potential Impact on Health 3Health News:Medical Groups Warn Of Climate Change's Potential Impact on Health 4Health News:Rituximab and fludarabine produce long-term remissions in CLL 2Health News:Brain imaging provides window into consciousness 2Health News:Brain imaging provides window into consciousness 3Health News:Brain imaging provides window into consciousness 4Health News:Brain imaging provides window into consciousness 5Health News:Newer Drug May Help Prevent Fracture in Men With Prostate Cancer 2Health News:Many Dialysis Patients at Risk for High Radiation Exposure 2Health News:Change in PSA level does not predict prostate cancer 2
7 mm strong curved blade. Round handle....
3 mm diameter roller blade in line with handle. Curved shaft. Flat handle. 15 mm from curve to tip....
5 mm diameter blade. Angled 45 degrees. Hexagonal handle....
0.5 mm wide x 1.5 mm long. Angled 20 degrees. Octagonal handle....
Medicine Products: